As of March 31, 2025, cash and cash equivalents were $2.9 million. The Company believes it has sufficient capital resources to fund its operations into late second quarter of 2025.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IMNN:
- IMNN Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Imunon announces first trial site initiated for Phase 3 OVATION 3 study
- Imunon announces data from Phase 1/2 OVATION 2 trial of IMNN-001
- Imunon announces IMNN-001 abstract accepted for oral presentation at 2025 ASCO
- Imunon files to sell 10M shares of common stock, warrants